STipe Therapeutics

OverviewSuggest Edit

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company develops drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders.
TypePrivate
Founded2018
Websitestipetherapeutics.com

Key People/Management at STipe Therapeutics

Claus Olesen

Claus Olesen

Co-Founder and CEO
Martin Roelsgaard Jakobsen

Martin Roelsgaard Jakobsen

Chief Scientific Officer
Show more

STipe Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

STipe Therapeutics total Funding

$21.9 m

STipe Therapeutics latest funding size

$21.87 m

Time since last funding

5 months ago

STipe Therapeutics investors

STipe Therapeutics's latest funding round in September 2019 was reported to be $21.9 m. In total, STipe Therapeutics has raised $21.9 m
Show all financial metrics

STipe Therapeutics Online and Social Media Presence

Embed Graph

STipe Therapeutics Frequently Asked Questions

  • When was STipe Therapeutics founded?

    STipe Therapeutics was founded in 2018.

  • Who are STipe Therapeutics key executives?

    STipe Therapeutics's key executives are Claus Olesen and Martin Roelsgaard Jakobsen.

  • Who are STipe Therapeutics competitors?

    Competitors of STipe Therapeutics include Ionova Life Science, BioNTech and MaxiVAX.